Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination

被引:31
|
作者
Bridle, Byram W. [1 ]
Nguyen, Andrew [2 ]
Salem, Omar [2 ]
Zhang, Liang [2 ]
Koshy, Sandeep [2 ]
Clouthier, Derek [2 ]
Chen, Lan [2 ]
Pol, Jonathan [2 ]
Swift, Stephanie L. [2 ]
Bowdish, Dawn M. E. [2 ]
Lichty, Brian D. [2 ]
Bramson, Jonathan L. [2 ]
Wan, Yonghong [2 ]
机构
[1] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada
[2] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada
来源
JOURNAL OF IMMUNOLOGY | 2016年 / 196卷 / 11期
基金
加拿大健康研究院;
关键词
DENDRITIC CELLS; MARGINAL ZONE; MARABA VIRUS; LYMPH-NODES; EFFECTOR; ACTIVATION; EXPRESSION; NAIVE; LOCALIZATION; GENERATION;
D O I
10.4049/jimmunol.1600106
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Effector T cells (T-EFF) are a barrier to booster vaccination because they can rapidly kill Ag-bearing APCs before memory T cells are engaged. We report in this study that i.v. delivery of rhabdoviral vectors leads to direct infection of follicular B cells in the spleen, where the earliest evidence of secondary T cell responses was observed. This allows booster immunizations to rapidly expand CD8(+) central memory T cells (T-CM) during the acute phase of the primary response that is dominated by TEFF. Interestingly, although the ablation of B cells before boosting with rhabdoviral vectors diminishes the expansion of memory T cells, B cells do not present Ags directly. Instead, depletion of CD11c(+) dendritic cells abrogates secondary T cell expansion, suggesting that virus-infected follicular B cells may function as an Ag source for local DCs to subsequently capture and present the Ag. Because TCM are located within B cell follicles in the spleen whereas TEFF cannot traffic through follicular regions, Ag production and presentation by follicular APCs represent a unique mechanism to secure engagement of TCM during an ongoing effector response. Our data offer insights into novel strategies for rapid expansion of CD8(+) T cells using prime-boost vaccines by targeting privileged sites for Ag presentation.
引用
收藏
页码:4587 / 4595
页数:9
相关论文
共 50 条
  • [21] Prime-boost vaccination with a live attenuated influenza vaccine elicits T cell-mediated cross-strain protective immunity
    Zeng, Mingtao
    Li, Junwei
    Arevalo, Maria
    Chen, Yanping
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [22] Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen
    Ali, Sumia
    Mulryan, Kate
    Taher, Taher
    Stern, Peter L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (02) : 165 - 180
  • [23] Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen
    Sumia Ali
    Kate Mulryan
    Taher Taher
    Peter L. Stern
    Cancer Immunology, Immunotherapy, 2007, 56 : 165 - 180
  • [24] Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA
    Mennuni, C
    Calvaruso, F
    Facciabene, A
    Aurisicchio, L
    Storto, M
    Scarselli, E
    Ciliberto, G
    La Monica, N
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (03) : 444 - 455
  • [25] Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model
    Lorenzen, Emma
    Contreras, Vanessa
    Olsen, Anja W.
    Andersen, Peter
    Desjardins, Delphine
    Rosenkrands, Ida
    Juel, Helene Baek
    Delache, Benoit
    Langlois, Sebastien
    Delaugerre, Constance
    Joubert, Christophe
    Dereuddre-Bosquet, Nathalie
    Bebear, Cecile
    De Barbeyrac, Bertille
    Touati, Arabella
    McKay, Paul F.
    Shattock, Robin J.
    Le Grand, Roger
    Follmann, Frank
    Dietrich, Jes
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
    Bolton, Diane L.
    Santra, Sampa
    Swett-Tapia, Cindy
    Custers, Jerome
    Song, Kaimei
    Balachandran, Harikrishnan
    Mach, Linh
    Naim, Hussein
    Kozlowski, Pamela A.
    Lifton, Michelle
    Goudsmit, Jaap
    Letvin, Norman
    Roederer, Mario
    Radosevic, Katarina
    VACCINE, 2012, 30 (41) : 5991 - 5998
  • [27] Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8+ T Cell Responses
    Ring, Sandra S.
    Krolik, Michal
    Hartmann, Fabienne
    Schmidt, Erika
    Ali, Omar Hasan
    Ludewig, Burkhard
    Kochanek, Stefan
    Flatz, Lukas
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 19 : 179 - 187
  • [28] Cytotoxic T cell responses to DNA vaccination: Dependence on antigen presentation via class II MHC
    Maecker, HT
    Umetsu, DT
    DeKruyff, RH
    Levy, S
    JOURNAL OF IMMUNOLOGY, 1998, 161 (12): : 6532 - 6536
  • [29] Late Boost Strategies of ALVAC-HIV/AIDSVAX B/E® Prime-boost Regimen (RV306) Increased Functional B Cell Responses and Frequency of Plasmablasts
    Chuenarom, Weerawan
    Pitisutthithum, Punnee
    Phuangngern, Yuwadee
    Nitayaphan, Sorachai
    Chariyalertsak, Suwat
    Kaewkungwal, Jaranit
    Kaewboon, Boot
    Phogat, Sanjay
    Karasavvas, Nicos
    Sinangil, Faruk
    Excler, Jean-Louis
    Robb, Merlin
    Michael, Nelson
    Kim, Jerome
    Desouza, Mark
    Connell, Robert O.
    Vasan, Sandhya
    Schuetz, Alexandra
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 393 - 393
  • [30] Early CD4+T Cell Responses Are Associated with Subsequent CD8+T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy
    Lhomme, Edouard
    Richert, Laura
    Moodie, Zoe
    Pasin, Chloe
    Kalams, Spyros A.
    Morgan, Cecilia
    Self, Steve
    De Rosa, Stephen C.
    Thiebaut, Rodolphe
    PLOS ONE, 2016, 11 (04):